Perjeta approved for use before surgery

Perjeta approved by the FDA today for patients with locally advanced, HER2+, inflammatory or early-stage breast cancer who are at high risk for recurrence or metastases used in combination with Herceptin and other chemotherapy before surgery.  After surgery, patients should continue on Herceptin to complete one year of treatment.

New combo in met pancreatic cancer

Abraxane in combination with gemcitabine is now approved as first-line treatment in metastatic pancreatic cancer.